ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Figure 1Loading Img

Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation:  Implications for Cardiotoxicity of Anticancer Anthracyclines

View Author Information
Departments of Drug Sciences and Cardiology and Cardiac Surgery, G. d'Annunzio University School of Medicine, Chieti, Italy
Cite this: Chem. Res. Toxicol. 2002, 15, 9, 1179–1189
Publication Date (Web):August 14, 2002
https://doi.org/10.1021/tx020055+
Copyright © 2002 American Chemical Society

    Article Views

    392

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options

    Abstract

    Lipid peroxidation has been proposed to mediate cardiotoxicity induced by doxorubicin (DOX) and other anticancer anthracyclines; however, there have been reports showing that DOX can also inhibit lipid peroxidation. Here we characterized the effects of DOX on the oxo-ferryl moiety [FeIVO, MbIV] of H2O2-activated myoglobin, a lipid oxidant likely formed in the heart during treatment with DOX. MbIV was formed in vitro by reacting 100 μM H2O2 with 50 μM horse heart metmyoglobin (MbIII). Spectral studies showed that DOX reduced MbIV to MbIII, half-maximal regeneration of MbIII occurring at ∼18 μM DOX. Comparisons between DOX, its aglycone doxorubicinone, and other approved or investigational anthracyclines or model compounds (daunorubicin, idarubicin, aclarubicin, and naphthazarin), showed that DOX reduced MbIV through the hydroquinone moiety of its tetracyclic ring. DOX inhibited MbIV-dependent peroxidation of arachidonic acid, suppressing the formation of thiobarbituric acid-reactive substances with an IC50 of ∼18 μM. Lipid peroxidation was inhibited also by the hydroquinone-containing daunorubicin and idarubicin but not by the hydroquinone-deficient aclarubicin; moreover, neither simple hydroquinone nor other known MbIV reductants (ascorbate, glutathione, and ergothioneine) reached measurable IC50s in a micromolar range. DOX-dependent inhibition of lipid peroxidation correlated with its ability to reduce MbIV to MbIII in competition with arachidonic acid (r = 0.83, P = 0.029); it did not correlate with its ability to scavenge other free radical species [like e.g., peroxyl radicals generated through the thermal decomposition of 2,2‘-azo-bis(2-amidinopropane)]. DOX reduced MbIV and inhibited lipid peroxidation also when H2O2, MbIII and arachidonic acid were reacted in cytosol of human myocardial biopsies, a model developed to predict the cardiotoxic mode of action of DOX in patients. These results illustrate “antioxidant” properties of DOX, mediated by reduction of MbIV to MbIII, and cast doubts on lipid peroxidation as a causative mechanism of anthracycline-induced cardiotoxicity.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

     P. M. and E. S. contributed equally to this paper.

     Department of Drug Sciences.

    §

     Department of Cardiology and Cardiac Surgery.

    *

     To whom correspondence should be addressed. Phone: 011-39-0871-3555320. Fax: 011-39-0871-3555356. E-mail: [email protected].

    Cited By

    This article is cited by 29 publications.

    1. Pierantonio Menna, Emanuela Salvatorelli and Giorgio Minotti. Anthracycline Degradation in Cardiomyocytes: A Journey to Oxidative Survival. Chemical Research in Toxicology 2010, 23 (1) , 6-10. https://doi.org/10.1021/tx9003424
    2. Pierantonio Menna, Emanuela Salvatorelli and Giorgio Minotti. 4′-Epidoxorubicin To Re-explore Anthracycline Degradation in Cardiomyocytes. Chemical Research in Toxicology 2009, 22 (6) , 978-983. https://doi.org/10.1021/tx900039p
    3. Zhiyong Cheng and, Yuanzong Li. What Is Responsible for the Initiating Chemistry of Iron-Mediated Lipid Peroxidation:  An Update. Chemical Reviews 2007, 107 (3) , 748-766. https://doi.org/10.1021/cr040077w
    4. Muthia Rajendran,, Paramasivam Manisankar,, Rathinasamy Gandhidasan, and, Ramachandran Murugesan. Free Radicals Scavenging Efficiency of a Few Naturally Occurring Flavonoids:  A Comparative Study. Journal of Agricultural and Food Chemistry 2004, 52 (24) , 7389-7394. https://doi.org/10.1021/jf0400718
    5. Ravi Tripathi, Abiodun Anifowose, Wen Lu, Xiaoxiao Yang, Binghe Wang. Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core. Journal of Enzyme Inhibition and Medicinal Chemistry 2022, 37 (1) , 2370-2381. https://doi.org/10.1080/14756366.2022.2116699
    6. Oreste Lanza, Armando Ferrera, Simone Reale, Giorgio Solfanelli, Mattia Petrungaro, Giacomo Tini Melato, Massimo Volpe, Allegra Battistoni. New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. Medical Sciences 2022, 10 (2) , 27. https://doi.org/10.3390/medsci10020027
    7. Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli, Roberto Levi. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. 2022, 365-409. https://doi.org/10.1016/bs.apha.2022.02.002
    8. Irina Borodina, Louise C. Kenny, Cathal M. McCarthy, Kalaivani Paramasivan, Etheresia Pretorius, Timothy J. Roberts, Steven A. van der Hoek, Douglas B. Kell. The biology of ergothioneine, an antioxidant nutraceutical. Nutrition Research Reviews 2020, 33 (2) , 190-217. https://doi.org/10.1017/S0954422419000301
    9. Samuel Steucek Tartakoff, Jennifer M. Finan, Ellis J. Curtis, Haley M. Anchukaitis, Danielle J. Couture, Samantha Glazier. Investigations into the DNA-binding mode of doxorubicinone. Organic & Biomolecular Chemistry 2019, 17 (7) , 1992-1998. https://doi.org/10.1039/C8OB02344A
    10. Emanuela Salvatorelli, Pierantonio Menna, Emilia Cantalupo, Massimo Chello, Elvio Covino, Federica I. Wolf, Giorgio Minotti. The concomitant management of cancer therapy and cardiac therapy. Biochimica et Biophysica Acta (BBA) - Biomembranes 2015, 1848 (10) , 2727-2737. https://doi.org/10.1016/j.bbamem.2015.01.003
    11. Toshiaki Miura. The peroxidase activity of ADM-Fe3+ cooperates with lipid peroxidation: The participation of hydroperoxide and hydroxyl radicals in the damage to proteins and DNA. Chemico-Biological Interactions 2015, 236 , 67-73. https://doi.org/10.1016/j.cbi.2015.04.019
    12. Emanuela Salvatorelli, Pierantonio Menna, Giorgio Minotti. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Future Cardiology 2015, 11 (4) , 363-366. https://doi.org/10.2217/FCA.15.35
    13. Джиоев, Inal Dzhioev, Джанаев, Robert Dzhanaev. Influence of doxorubicin on lipid peroxidation and heart histology in rats. Vladikavkaz Medico-Biological Bulletin 2015, 21 (31) , 33-36. https://doi.org/10.12737/17136
    14. Emanuela Salvatorelli, Pierantonio Menna, Mario Lusini, Elvio Covino, Giorgio Minotti. Doxorubicinolone Formation and Efflux: A Salvage Pathway against Epirubicin Accumulation in Human Heart. Journal of Pharmacology and Experimental Therapeutics 2009, 329 (1) , 175-184. https://doi.org/10.1124/jpet.108.149260
    15. Krzysztof J. Reszka, Bradley E. Britigan. Doxorubicin inhibits oxidation of 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonate) (ABTS) by a lactoperoxidase/H2O2 system by reacting with ABTS-derived radical. Archives of Biochemistry and Biophysics 2007, 466 (2) , 164-171. https://doi.org/10.1016/j.abb.2007.06.027
    16. Pierantonio Menna, Emanuela Salvatorelli, Giorgio Minotti. Doxorubicin Degradation in Cardiomyocytes. Journal of Pharmacology and Experimental Therapeutics 2007, 322 (1) , 408-419. https://doi.org/10.1124/jpet.107.122820
    17. Pierantonio Menna, Stefania Recalcati, Gaetano Cairo, Giorgio Minotti. An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovascular Toxicology 2007, 7 (2) , 80-85. https://doi.org/10.1007/s12012-007-0011-7
    18. Rosa Martínez, Mercedes Lacort, José Ignacio Ruiz-Sanz, M. Begoña Ruiz-Larrea. Ferrylmyoglobin impairs secretion of VLDL triacylglycerols from stored intracellular pools: Involvement of lipid peroxidation. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2007, 1771 (5) , 590-599. https://doi.org/10.1016/j.bbalip.2007.03.008
    19. Emanuela Salvatorelli, Pierantonio Menna, Luca Gianni, Giorgio Minotti. Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies. Journal of Pharmacology and Experimental Therapeutics 2007, 320 (2) , 790-800. https://doi.org/10.1124/jpet.106.116160
    20. Pierantonio Menna, Emanuela Salvatorelli, Luca Gianni, Giorgio Minotti. Anthracycline Cardiotoxicity. 2007, 21-44. https://doi.org/10.1007/128_2007_11
    21. Emanuela Salvatorelli, Simone Guarnieri, Pierantonio Menna, Giovanni Liberi, Antonio M. Calafiore, Maria A. Mariggiò, Alvaro Mordente, Luca Gianni, Giorgio Minotti. Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart. Journal of Biological Chemistry 2006, 281 (16) , 10990-11001. https://doi.org/10.1074/jbc.M508343200
    22. Krzysztof J. Reszka, Brett A. Wagner, Lynn M. Teesch, Bradley E. Britigan, Douglas R. Spitz, C. Patrick Burns. Inactivation of Anthracyclines by Cellular Peroxidase. Cancer Research 2005, 65 (14) , 6346-6353. https://doi.org/10.1158/0008-5472.CAN-04-2312
    23. Dimitri A. Svistunenko. Reaction of haem containing proteins and enzymes with hydroperoxides: The radical view. Biochimica et Biophysica Acta (BBA) - Bioenergetics 2005, 1707 (1) , 127-155. https://doi.org/10.1016/j.bbabio.2005.01.004
    24. Krzysztof J. Reszka, Laura H. Britigan, George T. Rasmussen, Brett A. Wagner, C. Patrick Burns, Bradley E. Britigan. Acetaminophen stimulates the peroxidative metabolism of anthracyclines. Archives of Biochemistry and Biophysics 2004, 427 (1) , 16-29. https://doi.org/10.1016/j.abb.2004.04.012
    25. Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, Gaetano Cairo, Luca Gianni. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews 2004, 56 (2) , 185-229. https://doi.org/10.1124/pr.56.2.6
    26. STEFANO FOGLI, PAOLA NIERI, MARIA CRISTINA BRESCHI. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. The FASEB Journal 2004, 18 (6) , 664-675. https://doi.org/10.1096/fj.03-0724rev
    27. Antonella Cartoni, Pierantonio Menna, Emanuela Salvatorelli, Daniela Braghiroli, Rossella Giampietro, Fabio Animati, Andrea Urbani, Piero Del Boccio, Giorgio Minotti. Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids. Journal of Biological Chemistry 2004, 279 (7) , 5088-5099. https://doi.org/10.1074/jbc.M306568200
    28. Giorgio Minotti, Stefania Recalcati, Pierantonio Menna, Emanuela Salvatorelli, Gianfranca Corna, Gaetano Cairo. Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms. 2004, 340-361. https://doi.org/10.1016/S0076-6879(04)78025-8
    29. Luca Gianni, Giacomo Grasselli, Sara Cresta, Alberta Locatelli, Lucia Viganò, Giorgio Minotti. Anthracyclines. 2003, 29-40. https://doi.org/10.1016/S0921-4410(03)21002-4

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect